HopeStage
Back to all studies
WithdrawnNCT03536390

A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD

This study evaluates the safety and effectiveness of Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT) for people with ADHD.

Medication studyAges 48–69 months
The study in practice

Understand this study

What is this study about?

This study evaluates the safety and effectiveness of Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT) for people with ADHD.

Who could participate?

This study is for people with ADHD. Listed age limits: 48 months to 69 months. Other eligibility criteria apply.

Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateEstimated: September 19, 2018
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
Pfizer
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Not clearly listed
Age range
From 48 Months to 69 Months
Official registry ID
NCT03536390
Official title
Show the full official title

A Phase 4, Double-blind, Randomized, Parallel Group, Placebo-controlled Study Of The Efficacy And Safety Of Methylphenidate Hydrochloride (Hcl) Extended Release Chewable Tablet (Erct) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder (Adhd)

Recruitment & locations

Withdrawn

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the safety and effectiveness of Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT) for people with ADHD.

Who is behind this study?

The study sponsor is Pfizer.

Does this study involve medication?

Yes. The study involves medication, including Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT) and Placebo.

Who can participate?

This study is for people with ADHD. Listed age limits: 48 months to 69 months. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as withdrawn.

Want to explore more studies?

Explore studies